A Novel Integrated Biomarker for Evaluation of Risk and Severity of Coronary Atherosclerosis, and Its Validation.

Victoria A MetelskayaNatalia E GavrilovaMaria V ZhatkinaElena B YarovayaOxana M Drapkina

Published in: Journal of personalized medicine (2022)

The i-BIO > 4 detected CA (GS > 0) with sensitivity of 87.9%, i-BIO ≥ 9 excluded patients without severe CA (GS < 35), specificity 79.8%. Validation of i-BIO confirmed the feasibility of i-BIO > 4 to separate patients with any CA with sensitivity 76.2%, and of i-BIO ≥ 9 to exclude atherosclerosis-free subjects with specificity of 84.0%.

Keyphrases

end stage renal disease
cardiovascular disease
ejection fraction
chronic kidney disease
newly diagnosed
protein kinase
heart failure
early onset
aortic stenosis
atrial fibrillation
transcatheter aortic valve replacement
aortic valve